Literature DB >> 158055

In vivo elimination by specific effector cells of an established syngeneic rat moloney virus-induced sarcoma.

E Fernandez-Cruz, B Halliburton, J D Feldman.   

Abstract

BN rats immunized subcutaneously with a viral induced tumor (MST) or with a chemical-induced fibrosarcoma (BC5) were donors of immune spleen cells. Samples of immune spleen cells were tested in vitro against MST and BC5 in a 51Cr release assay before culturing and after 7 days of culture with mitomycin C-treated MST and/or BC5 tumor cells (MSTMit, BC5Mit). These spleen cells were infused in vivo i.v. into x-rayed (400 R) and nonirradiated BN recipients that bore a vascularized and progressive (1 to 1.5 cm in diameter) subcutaneous MST or BC5. Spleen cells from untreated BN donor rats were also tested in vitro and in vivo as controls. Established MST were specifically eliminated by spleen cells immune to MST after culture with MSTMit, but not by spleen cells immune to MST without further culture nor by cultured or uncultured BC5 immune spleen cells and control spleen cells. Also, the growth of BC5 was not affected by MST immune spleen cells cultured for 7 days with MST and/or BC5. Elimination of Moloney sarcoma (MST) in vivo occurred in less than 35 days and was correlated with the generation of cytotoxicity in vitro since only MST immune spleen cells cultured with MSTMit were able to augment significantly their cytotoxic capability in vitro.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 158055

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Amplification of altered self-reactive cytolytic T lymphocyte responses by cloned, allospecific human Th cells.

Authors:  S M Friedman; A Green; C Russo; D N Posnett; D Diffley; M K Crow
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

Review 2.  The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.

Authors:  S E Ettinghausen; S A Rosenberg
Journal:  Springer Semin Immunopathol       Date:  1986

3.  Long-term immunological memory in the resistance of rats to transplanted intracerebral 9L gliosarcoma (9LGS) following subcutaneous immunization with 9LGS cells.

Authors:  H M Smilowitz; D D Joel; D N Slatkin; P L Micca; M M Nawrocky; K Youngs; W Tu; J A Coderre
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

4.  Adoptive chemoimmunotherapy of a syngeneic murine lymphoma with long-term lymphoid cell lines expanded in T cell growth factor.

Authors:  T J Eberlein; M Rosenstein; P Spiess; R Wesley; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

5.  Immunomodulatory effects of systemic low-dose recombinant interleukin-2 and lymphokine-activated killer cells in humans.

Authors:  T J Eberlein; M L Rodrick; A F Massaro; S E Jung; J A Mannick; D D Schoof
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

6.  Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.

Authors:  M A Cheever; P D Greenberg; A Fefer; S Gillis
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

7.  Adoptive immunotherapy mediated by anti-TCR/IL-2-activated tumour-draining lymph node cells.

Authors:  S Mitsuma; H Yoshizawa; K Ito; H Moriyama; M Wakabayashi; T Chou; M Arakawa; S Shu
Journal:  Immunology       Date:  1994-09       Impact factor: 7.397

8.  Failure of specific adoptive immunotherapy owing to survival and outgrowth of variant cells.

Authors:  D L Hines
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

9.  Clinical adoptive chemoimmunotherapy with allogeneic alloactivated HLA-haploidentical lymphocytes: controlled induction of graft-versus-host-reactions.

Authors:  P C Kohler; J A Hank; D Z Minkoff; P M Sondel
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

10.  T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases.

Authors:  E S Dye; R J North
Journal:  J Exp Med       Date:  1981-10-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.